ADMA Biologics, Inc. (ADMA) Balance Sheet

The near-tripling of debt within two quarters appears tied to aggressive capital returns, including $130.2M in buybacks during 2026Q1, per cash flow statements. This shift from a nearly unlevered balance sheet to moderate leverage suggests management is confident in cash flow durability, but it introduces new interest expense and refinancing considerations. Investors should monitor whether the increased debt is funding growth or merely accelerating shareholder distributions.

The debt increase coincides with substantial share repurchases, suggesting the company is borrowing to return capital rather than to fund organic expansion. While the absolute leverage remains moderate compared to peers like Grifols (D/E 1.15), the speed of the increase warrants scrutiny. If operating cash flow does not continue to grow, the added debt service could strain liquidity, though current cash of $136.0M provides a near-term cushion.

The modest goodwill suggests ADMA's growth has been organic, avoiding overpayment risks common in biotech M&A. The steady PPE base, despite revenue growth, implies efficient use of existing facilities, though the single-site concentration in Boca Raton remains a key operational risk. The asset mix underscores a vertically integrated model where tangible assets and plasma inventory drive value, not intangibles.

The rapid accumulation of retained earnings, driven by net margins exceeding 28% in recent quarters, signals a fundamental shift from a loss-making R&D entity to a profitable commercial operator. However, the aggressive buyback program, which reduced share count, also boosts per-share metrics but may be masking the full extent of equity rebuilding. The negative retained earnings balance still indicates a history of dilution and losses, but the trend is clearly favorable.

Despite the debt increase, liquidity remains robust, with current assets far exceeding current liabilities. The cash position alone covers roughly 67% of total debt, suggesting no imminent solvency risk. However, the high current ratio may also indicate inefficiency in deploying working capital, though in a plasma business with long inventory cycles, this is prudent. The buffer supports continued investment in collection centers and manufacturing, but the single-site risk remains the primary threat to liquidity.